All In Biotech

Drug Trial Radar · NCT05744427

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

725

Planned (sponsor's estimate)

Start

Mar 15, 2023

Primary completion

Jul 30, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, multicenter study of phase I/II in Chinese subjects with unresectable locally advanced/metastatic solid tumors. It is divided into the dose escalation period and the cohort expansion period. A total of 8 dose groups (Q3W on the first day of intravenous administration) were designed in the dose escalation period. The initial dose was 1.0mg/kg administered Q3W, with a DLT observation period of 21 days. In the dose expansion phase, 7 cohorts were established.

Conditions

  • Advanced Solid Tumor

Interventions

  • JSKN003Drug

    JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT (dose escalation period) in phase 1.Time frame: Up to 12 months
  2. Maximum Tolerated Dose (MTD) or RP2D in phase 1。Time frame: Up to 12 months
  3. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events in phase 1.Time frame: Throughout the duration of the study, approximately 2 years
  4. Objective Response Rate (ORR) in phase 2Time frame: Throughout the duration of the study, approximately 2 years

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Friendship Hospital

    Beijing, China

  • Beijing Luhe Hospital

    Beijing, China

  • Hunan Cancer Hospital

    Changsha, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China

  • Sun Yat-sen University Cancer Prevention Center

    Guangzhou, China

  • Affiliated Cancer Hospital of Harbin Medical University

    Ha’erbin, China

  • Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Anhui Provincal Hospital

    Hefei, China

  • Shandong Cancer Hospital

    Jinan, China

  • Linyi City Cancer Hospital

    Linyi, China

  • Linyi City People's Hospital

    Linyi, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • Gulou Hospital Affiliated to Nanjing University School of Medicine

    Nanjing, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Jiangsu Provincial People's Hospital

    Nanjing, China

  • The First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial People's Hospital

    Nanjing, China

  • Affiliated Cancer Hospital of Guangxi Medical University

    Nanning, China

  • Nantong Cancer Hospital

    Nantong, China

  • Affiliated Hospital of Qingdao University

    Qingdao, China

  • Affiliated Cancer Hospital of Fudan University

    Shanghai, China

  • Changhai Hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Shanghai East Hospital

    Shanghai, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, China

  • Xuzhou Central Hospital

    Xuzhou, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.